Phathom Pharmaceuticals, Inc.

Sebela’s potassium-competitive acid blocker (P-CAB) tegoprazan demonstrated superior efficacy to a proton pump inhibitor (PPI) in a Phase III trial in patients with gastroesophageal reflux disease (GE

The pace of new biopharmaceutical financings has slowed as summer enters the last sleepy weeks of August, but the handful of recent significant funding announcements have been quite large, including

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. OcuMension Signs Stock-for-Rights

Phathom Pharmaceuticals, Inc. already launched the heartburn reliever Voquezna (vonoprazan) in November 2023, but US Food and Drug Administration approval in an expanded indication will make the trea